Abstract: Topical naproxen formulations comprising long chain monounsaturated fatty acids, long chain monounsaturated fatty alcohols, terpenes, or combinations thereof and a solvent mixture comprising ethanol, propylene glycol, 2-(2-Ethoxyethoxy)ethanol, and optionally dimethylsulfoxide (“DMSO”), wherein the formulation comprises about 5.0 wt % or less water and is preferably anhydrous.

Abstract: The present invention recognizes that there exists a long felt need for devices that can dispense a compound in a measured aliquot, A first aspect of the present invention generally relates to a ball valve device. A second aspect of the present invention generally relates to a method of making a ball valve of the present invention. A third aspect of the present, invention generally relates to a method of dispensing a compound using a ball valve device of the present invention.

Abstract: A topical cyclooxygenase (COX) inhibitor formulation comprising an inhibitor of COX-1 and/or COX-2, one or more long chain monounsaturated fatty acids, long chain monounsaturated fatty alcohols, terpenes, or combinations thereof; and a solvent mixture comprising ethanol, propylene glycol, 2-(2-Ethoxyethoxy)ethanol, and optionally dimethylsulfoxide.

Abstract: In accordance with the present disclosure, there are provided formulations comprising: (a) at least one active agent; (b) an oil, and optionally a thickener therefor; (c) an organic solvent, and a thickener therefor; and (d) an oil and/or solvent soluble skin penetration enhancer; wherein: said formulation comprises <10 wt % water; and said formulation optionally forms a thixotropic thinning gel. Also provided are gels comprising oil and organic solvent, methods for preparing same and methods for the topical delivery of an active agent to a subject in need thereof.

Abstract: A topical cyclooxygenase (COX) inhibitor formulation comprising an inhibitor of COX-1 and/or COX-2, one or more long chain monounsaturated fatty acids, long chain monounsaturated fatty alcohols, terpenes, or combinations thereof; and a solvent mixture comprising ethanol, propylene glycol, 2-(2-Ethoxyethoxy)ethanol, and optionally dimethylsulfoxide.

Abstract: In accordance with the present disclosure, there are provided formulations comprising: (a) at least one active agent; (b) an oil, and optionally a thickener therefor; (c) an organic solvent, and a thickener therefor; and (d) an oil and/or solvent soluble skin penetration enhancer; wherein: said formulation comprises <10 wt % water; and said formulation optionally forms a thixotropic thinning gel. Also provided are gels comprising oil and organic solvent, methods for preparing same and methods for the topical delivery of an active agent to a subject in need thereof.

Abstract: A topical cyclooxygenase (COX) inhibitor formulation comprising an inhibitor of COX-1 and/or COX-2, one or more long chain monounsaturated fatty acids, long chain monounsaturated fatty alcohols, terpenes, or combinations thereof; and a solvent mixture comprising ethanol, propylene glycol, 2-(2-Ethoxyethoxy)ethanol, and optionally dimethylsulfoxide.

Abstract: In accordance with the present disclosure, there are provided formulations comprising: (a) at least one active agent; (b) an oil, and optionally a thickener therefor; (c) an organic solvent, and a thickener therefor; and (d) an oil and/or solvent soluble skin penetration enhancer; wherein: said formulation comprises <10 wt % water; and said formulation optionally forms a thixotropic thinning gel. Also provided are gels comprising oil and organic solvent, methods for preparing same and methods for the topical delivery of an active agent to a subject in need thereof.

Abstract: The formulations have an antimicrobial, antiviral, and anti-pathogenic composition that combines, in various forms, a redox-active polyphenol, an oxidizing agent, and/or a redox-active, transition metal ion and/or electrochemical potential. The composition relates to methods for decreasing or eliminating the infectivity, morbidity, and rate of mortality associated with a variety of pathogenic organisms and viruses. The present invention also relates to methods and compositions for treating herpes simplex and HIV viruses and drug-resistant bacteria, and for decontaminating areas colonized or otherwise infected by pathogenic organisms and viruses. Moreover, the present invention relates to methods, compositions, electrochemical devices, and storage containers for decreasing the infectivity of pathogenic organisms in pharmaceuticals, medical devices, personal care products, recreational products, and foodstuffs.

Abstract: To maximize and maintain the antioxidant or pro-oxidant state for foods, beverages, personal care products, cosmetics, nutritional supplements, reagents, analytical standards, medical device formulations, pharmaceutical preparations or drags, the present invention discloses methods and devices to control redox equilibrium of such preparations throughout the processing steps and storage prior to, or at, the time of administration or use. The preparations (solid or liquid form) can then be stored in a redox-controlled container, package or applicator as described in the specification. Foods, beverages, personal care products, cosmetics, nutritional supplements, reagents, analytical standards, medical device formulations, pharmaceutical preparations and drugs stored in reactive oxidation states can be activated and stabilized by electrical voltages applied with a small battery and electrodes designed into the applicator, container or package.